LGND Relative Valuation
LGND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LGND is overvalued; if below, it's undervalued.
Historical Valuation
Ligand Pharmaceuticals Inc (LGND) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.58. The fair price of Ligand Pharmaceuticals Inc (LGND) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：188.50
Fair
50.02
PE
1Y
3Y
5Y
Trailing
Forward
25.01
EV/EBITDA
Ligand Pharmaceuticals Inc. (LGND) has a current EV/EBITDA of 25.01. The 5-year average EV/EBITDA is 18.36. The thresholds are as follows: Strongly Undervalued below 6.00, Undervalued between 6.00 and 12.18, Fairly Valued between 24.54 and 12.18, Overvalued between 24.54 and 30.72, and Strongly Overvalued above 30.72. The current Forward EV/EBITDA of 25.01 falls within the Overvalued range.
45.60
EV/EBIT
Ligand Pharmaceuticals Inc. (LGND) has a current EV/EBIT of 45.60. The 5-year average EV/EBIT is -87.68. The thresholds are as follows: Strongly Undervalued below -704.49, Undervalued between -704.49 and -396.09, Fairly Valued between 220.73 and -396.09, Overvalued between 220.73 and 529.14, and Strongly Overvalued above 529.14. The current Forward EV/EBIT of 45.60 falls within the Historic Trend Line -Fairly Valued range.
16.07
PS
Ligand Pharmaceuticals Inc. (LGND) has a current PS of 16.07. The 5-year average PS is 10.72. The thresholds are as follows: Strongly Undervalued below 6.55, Undervalued between 6.55 and 8.64, Fairly Valued between 12.81 and 8.64, Overvalued between 12.81 and 14.90, and Strongly Overvalued above 14.90. The current Forward PS of 16.07 falls within the Strongly Overvalued range.
26.28
P/OCF
Ligand Pharmaceuticals Inc. (LGND) has a current P/OCF of 26.28. The 5-year average P/OCF is 10.92. The thresholds are as follows: Strongly Undervalued below -7.05, Undervalued between -7.05 and 1.93, Fairly Valued between 19.90 and 1.93, Overvalued between 19.90 and 28.88, and Strongly Overvalued above 28.88. The current Forward P/OCF of 26.28 falls within the Overvalued range.
42.85
P/FCF
Ligand Pharmaceuticals Inc. (LGND) has a current P/FCF of 42.85. The 5-year average P/FCF is 7.65. The thresholds are as follows: Strongly Undervalued below -250.54, Undervalued between -250.54 and -121.44, Fairly Valued between 136.75 and -121.44, Overvalued between 136.75 and 265.84, and Strongly Overvalued above 265.84. The current Forward P/FCF of 42.85 falls within the Historic Trend Line -Fairly Valued range.
Ligand Pharmaceuticals Inc (LGND) has a current Price-to-Book (P/B) ratio of 3.90. Compared to its 3-year average P/B ratio of 2.30 , the current P/B ratio is approximately 69.63% higher. Relative to its 5-year average P/B ratio of 2.39, the current P/B ratio is about 63.10% higher. Ligand Pharmaceuticals Inc (LGND) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 4.92%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 4.45% , the current FCF yield is about -100.00% lower.
3.90
P/B
Median3y
2.30
Median5y
2.39
0.81
FCF Yield
Median3y
4.92
Median5y
4.45
Competitors Valuation Multiple
The average P/S ratio for LGND's competitors is 0.00, providing a benchmark for relative valuation. Ligand Pharmaceuticals Inc Corp (LGND) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 122.85%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LGND increased by 75.92% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 8.53 to 75.69.
The secondary factor is the Revenue Growth, contributed 122.85%to the performance.
Overall, the performance of LGND in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Ligand Pharmaceuticals Inc (LGND) currently overvalued or undervalued?
What is Ligand Pharmaceuticals Inc (LGND) fair value?
How does LGND's valuation metrics compare to the industry average?
What is the current P/B ratio for Ligand Pharmaceuticals Inc (LGND) as of Dec 05 2025?
What is the current FCF Yield for Ligand Pharmaceuticals Inc (LGND) as of Dec 05 2025?
What is the current Forward P/E ratio for Ligand Pharmaceuticals Inc (LGND) as of Dec 05 2025?